Immunovant shares are down about 5.4% to roughly $24.12 in a pullback that appears driven by catalyst-related positioning rather than fresh headline news. The company has guided that topline results from two Phase 3 studies of batoclimab in active, moderate-to-severe thyroid eye disease (TED) are expected in the first half of calendar 2026, keeping investors focused on a potentially high-volatility readout window. (immunovant.com)

With the TED Phase 3 readout expected within the current half-year window, IMVT can trade like an event-driven biotech: gains can be faded and risk reduced as investors rebalance ahead of binary clinical outcomes. The lack of an obvious same-day press release or new trial update amplifies the likelihood that today’s move is flow-driven—profit-taking after prior strength and hedging into the upcoming data catalyst—rather than a change in the fundamental thesis.

TED remains a key near-term focus because batoclimab is already in Phase 3, while Immunovant’s next-generation FcRn program (IMVT-1402) is progressing across multiple potentially registrational studies with major readouts later in 2026. In its February 2026 corporate update, the company reiterated expectations for 2H 2026 topline data in difficult-to-treat rheumatoid arthritis (D2T RA) and a proof-of-concept readout in cutaneous lupus erythematosus (CLE), adding additional catalyst density beyond TED. (immunovant.com)

Investors will monitor for any updated timing on the Phase 3 TED topline release within 1H 2026, plus any details on endpoints, safety, and consistency across the two studies once results are out. Near-term trading can also react to any new 8-K/SEC updates, trial registry changes, or shifts in guidance around IMVT-1402 milestones as the company moves through a busy 2026 catalyst calendar. (immunovant.com)